Mapping large numbers of results may take a few moments.
|Company StrideBio Inc.||Activity: Research and Development||Company Description StrideBio develops engineered viral vectors for gene therapy for the treatment of rare diseases. StrideBio's technology engine utilizes structure-inspired design to engineer AAV vectors which can escape pre-existing neutralizing antibodies (NAbs).||Location Research Triangle Park|
|Company AskBio||Activity: Research and Development||Company Description Asklepios BioPharmaceutical (AskBio) uses adeno-associated virus (AAV) technology to develop and manufacture gene therapies for rare diseases and other genetic disorders.||Location Research Triangle Park|
|Company bluebird bio Inc.||Activity: Production and Manufacturing||Company Description bluebird bio develops gene therapies and cancer immunotherapies for the treatment of genetic diseases and cancer. At its Durham site, bluebird produces lentiviral vectors for the company's gene and cell therapies.||Location Durham|
|Company Cellectis||Activity: Production and Manufacturing||Company Description Cellectis develops blood and bone marrow cancer cell therapies. The Raleigh location is its North American manufacturing plant.||Location Raleigh|
|Company Novartis Gene Therapies||Activity: Production and Manufacturing||Company Description Novartis Gene Therapies develops and commercializes gene therapy products for neurological genetic diseases. The Durham site is Novartis Gene Therapies' manufacturing operations.||Location Durham|
|Company Precision BioSciences Inc.||Activity: Research and Development||Company Description Precision BioSciences utilizes a proprietary genome editing method called ARCUS to treat cancers and genetic diseases, and enable the development of safer, more productive food sources.||Location Durham|
|Company Precision Biosciences Manufacturing Center for Advanced Therapeutics||Activity: Production and Manufacturing||Company Description Precision BioSciences utilizes a proprietary genome editing method called ARCUS to treat cancers and genetic diseases. The MCAT facility produces genome-edited, off-the-shelf CAR T-cell therapy products.||Location Research Triangle Park|